H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Can-Fite BioPharma (NYSE: CANF) today and set a price target of $8. The company’s shares closed on Friday at $1.17, close to its 52-week low of $1.12.
Kolbert noted:
“Our therapeutic models are patient-based and reflect our assumptions for the product launch dates, product attributes, and pricing, to determine the future revenue streams. We apply a probability of success in these models.”
According to TipRanks.com, Kolbert has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.1% and a 38.2% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Keryx Biopharma.
Currently, the analyst consensus on Can-Fite BioPharma is a Moderate Buy with an average price target of $8.
See today’s analyst top recommended stocks >>
Based on Can-Fite BioPharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $1.75 million. In comparison, last year the company had a GAAP net loss of $2.02 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602.
